Tag: Epidiolex

GW Pharma Progresses Towards Epidiolex FDA Submission

GW Announces New Epidiolex® (CBD) Positive Phase 3 Data in Dravet Syndrome and Lennox-Gastaut Syndrome – Posters Presented at American Epilepsy Society Annual Meeting – – New data includes...
- December 5th, 2016 at 7:39 am

GW Pharma Soars on Takeover Rumors

Shares in GW Pharma (NASDAQ: GWPH) (AIM: GWP) shot up in trading today after Reuters posted an exclusive report that the company has hired investment bank Morgan Stanley in...
- September 7th, 2016 at 3:47 pm

GW Pharma Phase 3 Data Due Soon

The Financial Times shared a great history of the ups and downs  of GW Pharma (NASDAQ: GWPH), which will soon report the results of the first of four Phase...
- February 1st, 2016 at 9:42 am

This Recent Federal Law Could Help GW Pharma's Epidiolex

GW Pharmaceuticals (NASDAQ: GWPH) reported its fiscal year-end results today and held a conference call after the market closed.  One of the more interesting parts of the prepared remarks involved...
- December 7th, 2015 at 6:20 pm